Erschienen in:
01.10.2018 | Letter to the Editor
Author’s Reply to Webster and Woollett: “The End of Phase 3 Clinical Trials in Biosimilars Development?”
verfasst von:
Francois-Xavier Frapaise
Erschienen in:
BioDrugs
|
Ausgabe 5/2018
Einloggen, um Zugang zu erhalten
Excerpt
I thank Drs. Webster and Woollett [
1] for their letter to the editor. It was my main goal in authoring this article to trigger a discussion between biosimilar specialists on the relevance of the current clinical development model. I agree with Drs. Webster and Woollett that it may be possible to spend less than $50 million for a typical phase 3 biosimilar trial; the amount mentioned in my article corresponds to my own experience with large international Contract Research Organizations, providing full service and including the sourcing cost. …